Peter the Bridge, Saint Petersburg, Russia

News from NEOMED

NEO6860 Clinical Results to be Presented at the Pain & Migraine Therapeutics Summit

20 September 2017|Announcement| No Comments
- NEO6860 is a modality selective TRPV1 antagonist explored for the treatment of OA pain - - A phase II PoC Study is now completed - - NEO6860 is safe and exhibits an analgesic effect - Montreal, September 20, 2017 - The NEOMED Institute announced today that it will present two posters on the clini

Read complete news

PARG Inhibitor Collaboration – BioAuxilium and NEOMED

18 September 2017|Announcement| No Comments
High Throughput Screening Assay for PARG Inhibitors Montreal, September 18th, 2017 - BioAuxilium Research Inc. and the NEOMED Institute announced today the result of a successful collaboration whereby BioAuxilium has developed and validated for NEOMED a custom TR-FRET-based high-throughput screening (HT

Read complete news

GSK and NEOMED Launch $2M Discovery Fund to Accelerate Novel Science and Technologies in Quebec

21 June 2017| No Comments
The fund aims to advance and de-risk innovative and early stage human therapeutic discoveries arising from academic and research institutes in Quebec Laval, QC, June 21, 2017 – GlaxoSmithKline Inc. (GSK) and NEOMED Institute (NEOMED) are pleased to announce that they

Read complete news


20 June 2017|Announcement| No Comments
San Diego, June 20, 2017 – The NEOMED Institute and GIP GENOPOLE – the promoters of two successful national models for the development of biotechnology ecosystems - today announced the signature of a strategic cooperation agreement to explore and develop common initiatives to establish and sustain a collaborati

Read complete news

© 2017 NEOMED Institute. All Rights Reserved. // Solutions Web Globalia